Genmab A/S

CPSE:GMAB Stock Report

Market Cap: DKK 110.7b

Genmab Management

Management criteria checks 2/4

Genmab's CEO is Jan G.J. de Winkel, appointed in Jun 2010, has a tenure of 15.83 years. total yearly compensation is $10.70M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth DKK1.19B. The average tenure of the management team and the board of directors is 6.1 years and 8.1 years respectively.

Key information

Jan G.J. de Winkel

Chief executive officer

US$10.7m

Total compensation

CEO salary percentage14.02%
CEO tenure15.8yrs
CEO ownership1.1%
Management average tenure6.1yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Jul 31
Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11
Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
User avatar

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

CEO Compensation Analysis

How has Jan G.J. de Winkel's remuneration changed compared to Genmab's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$11mUS$2m

US$963m

Sep 30 2025n/an/a

US$2b

Jun 30 2025n/an/a

US$1b

Mar 31 2025n/an/a

US$1b

Dec 31 2024US$8mUS$1m

US$1b

Sep 30 2024n/an/a

US$702m

Jun 30 2024n/an/a

US$798m

Mar 31 2024n/an/a

US$791m

Jan 01 2024n/an/a

US$631m

Sep 30 2023n/an/a

US$590m

Jun 30 2023n/an/a

US$680m

Mar 31 2023n/an/a

US$757m

Dec 31 2022US$6mUS$1m

US$785m

Sep 30 2022n/an/a

US$745m

Jun 30 2022n/an/a

US$558m

Mar 31 2022n/an/a

US$354m

Dec 31 2021US$6mUS$1m

US$452m

Sep 30 2021n/an/a

US$448m

Jun 30 2021n/an/a

US$401m

Mar 31 2021n/an/a

US$880m

Dec 31 2020US$6mUS$1m

US$781m

Sep 30 2020n/an/a

US$889m

Jun 30 2020n/an/a

US$853m

Mar 31 2020n/an/a

US$349m

Dec 31 2019US$5mUS$1m

US$325m

Compensation vs Market: Jan G.J.'s total compensation ($USD10.70M) is above average for companies of similar size in the Danish market ($USD5.59M).

Compensation vs Earnings: Jan G.J.'s compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Jan G.J. de Winkel (64 yo)

15.8yrs
Tenure
US$10,700,000
Compensation

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Leadership Team

NamePositionTenureCompensationOwnership
Jan G.J. de Winkel
Co-Founder15.8yrsUS$10.70m1.07%
DKK 1.2b
Anthony Pagano
Executive VP & CFO6.1yrsUS$4.70m0.017%
DKK 18.6m
Rayne Waller
Executive VP & Chief Technical Operations Officer1.7yrsUS$2.70mno data
Gregory David Mueller
Executive VPless than a yearUS$1.80mno data
Christopher Cozic
Executive VP & Chief People Officer8.4yrsUS$3.40mno data
Martine van Vugt
Executive VP & Chief Strategy Officer12.3yrsUS$2.40mno data
Martin Schultz
Senior Directorno dataUS$300.00k0.0014%
DKK 1.6m
Judith Klimovsky
Executive VP & Chief Development Officer9.2yrsUS$5.40m0.025%
DKK 28.0m
Tahamtan Ahmadi
Executive VP5.1yrsUS$5.20m0.016%
DKK 18.1m
Mijke Zachariasse
VP, Head of Antibody Research Materials & Directorno dataUS$300.00k0.0014%
DKK 1.5m
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Directorno dataUS$100.00k0.00013%
DKK 144.0k
Brad Bailey
Executive VP & Chief Commercial Officer1.7yrsUS$2.10mno data
6.1yrs
Average Tenure
53yo
Average Age

Experienced Management: GMAB's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Martin Schultz
Senior Director4.3yrsUS$300.00k0.0014%
DKK 1.6m
Mijke Zachariasse
VP, Head of Antibody Research Materials & Director7.1yrsUS$300.00k0.0014%
DKK 1.5m
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Director4.3yrsUS$100.00k0.00013%
DKK 144.0k
Michael Kavanagh
Senior Director1.3yrsUS$200.00k0.00086%
DKK 952.4k
Anders Pedersen
Non-Independent Director22.4yrsUS$400.00k0.013%
DKK 13.9m
Elizabeth O'Farrell
Independent Director4.1yrsUS$400.00k0.0031%
DKK 3.4m
Deirdre Connelly
Independent Chairman of the Board9.1yrsUS$600.00k0.011%
DKK 11.9m
Rolf Hoffmann
Independent Director9.1yrsUS$400.00k0.0062%
DKK 6.8m
Pernille Erenbjerg
Independent Deputy Chairman11.3yrsUS$400.00k0.0089%
DKK 9.9m
Paolo Paoletti
Independent Director11.3yrsUS$300.00k0.0041%
DKK 4.5m
8.1yrs
Average Tenure
59.5yo
Average Age

Experienced Board: GMAB's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/19 15:15
End of Day Share Price 2026/04/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 40 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily FieldBarclays
James GordonBarclays
Xue ChenBarclays